In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GemVax Pancreatic Cancer Vaccine Set For First Launch, By Samsung

This article was originally published in PharmAsia News

Executive Summary

Despite an earlier Phase III setback for its therapeutic pancreatic cancer vaccine Riavax, GemVax & KAEL Co. has signed a new licensing deal with Samsung Pharm under which the latter will handle manufacturing, supplying and commercializing of the first-in-class product in South Korea.

Advertisement
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

SC088791

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel